Sarah M Ryan1, Tasha E Fingerlin2,3,4, Margaret Mroz5, Briana Barkes5, Nabeel Hamzeh6, Lisa A Maier5,7,8, Nichole E Carlson2. 1. Dept of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA sarah.m.ryan@cuanschutz.edu. 2. Dept of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA. 3. Dept of Epidemiology, Colorado School of Public Health, Aurora, CO, USA. 4. Dept of Biomedical Research, National Jewish Health, Denver, CO, USA. 5. Dept of Medicine, National Jewish Health, Denver, CO, USA. 6. Dept of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 7. Dept of Medicine, University of Colorado, Denver, CO, USA. 8. Dept of Environmental and Occupational Health, Colorado School of Public Health, Aurora, CO, USA.
Abstract
INTRODUCTION: Pulmonary sarcoidosis is a rare heterogeneous lung disease of unknown aetiology, with limited treatment options. Phenotyping relies on clinical testing including visual scoring of chest radiographs. Objective radiomic measures from high-resolution computed tomography (HRCT) may provide additional information to assess disease status. As the first radiomics analysis in sarcoidosis, we investigate the potential of radiomic measures as biomarkers for sarcoidosis, by assessing 1) differences in HRCT between sarcoidosis subjects and healthy controls, 2) associations between radiomic measures and spirometry, and 3) trends between Scadding stages. METHODS: Radiomic features were computed on HRCT in three anatomical planes. Linear regression compared global radiomic features between sarcoidosis subjects (n=73) and healthy controls (n=78), and identified associations with spirometry. Spatial differences in associations across the lung were investigated using functional data analysis. A subanalysis compared radiomic features between Scadding stages. RESULTS: Global radiomic measures differed significantly between sarcoidosis subjects and controls (p<0.001 for skewness, kurtosis, fractal dimension and Geary's C), with differences in spatial radiomics most apparent in superior and lateral regions. In sarcoidosis subjects, there were significant associations between radiomic measures and spirometry, with a large association found between Geary's C and forced vital capacity (FVC) (p=0.008). Global radiomic measures differed significantly between Scadding stages (p<0.032), albeit nonlinearly, with stage IV having more extreme radiomic values. Radiomics explained 71.1% of the variability in FVC compared with 51.4% by Scadding staging alone. CONCLUSIONS: Radiomic HRCT measures objectively differentiate disease abnormalities, associate with lung function and identify trends in Scadding stage, showing promise as quantitative biomarkers for pulmonary sarcoidosis.
INTRODUCTION:Pulmonary sarcoidosis is a rare heterogeneous lung disease of unknown aetiology, with limited treatment options. Phenotyping relies on clinical testing including visual scoring of chest radiographs. Objective radiomic measures from high-resolution computed tomography (HRCT) may provide additional information to assess disease status. As the first radiomics analysis in sarcoidosis, we investigate the potential of radiomic measures as biomarkers for sarcoidosis, by assessing 1) differences in HRCT between sarcoidosis subjects and healthy controls, 2) associations between radiomic measures and spirometry, and 3) trends between Scadding stages. METHODS: Radiomic features were computed on HRCT in three anatomical planes. Linear regression compared global radiomic features between sarcoidosis subjects (n=73) and healthy controls (n=78), and identified associations with spirometry. Spatial differences in associations across the lung were investigated using functional data analysis. A subanalysis compared radiomic features between Scadding stages. RESULTS: Global radiomic measures differed significantly between sarcoidosis subjects and controls (p<0.001 for skewness, kurtosis, fractal dimension and Geary's C), with differences in spatial radiomics most apparent in superior and lateral regions. In sarcoidosis subjects, there were significant associations between radiomic measures and spirometry, with a large association found between Geary's C and forced vital capacity (FVC) (p=0.008). Global radiomic measures differed significantly between Scadding stages (p<0.032), albeit nonlinearly, with stage IV having more extreme radiomic values. Radiomics explained 71.1% of the variability in FVC compared with 51.4% by Scadding staging alone. CONCLUSIONS: Radiomic HRCT measures objectively differentiate disease abnormalities, associate with lung function and identify trends in Scadding stage, showing promise as quantitative biomarkers for pulmonary sarcoidosis.
Authors: M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui Journal: J Natl Cancer Inst Date: 2001-07-18 Impact factor: 13.506
Authors: Dag Wormanns; Gerhard Kohl; Ernst Klotz; Anke Marheine; Florian Beyer; Walter Heindel; Stefan Diederich Journal: Eur Radiol Date: 2003-11-13 Impact factor: 5.315
Authors: James C Ross; Peter J Castaldi; Michael H Cho; Junxiang Chen; Yale Chang; Jennifer G Dy; Edwin K Silverman; George R Washko; Raul San Jose Estepar Journal: IEEE Trans Med Imaging Date: 2017-01 Impact factor: 10.048
Authors: D A Van den Heuvel; P A de Jong; P Zanen; H W van Es; J P van Heesewijk; M Spee; J C Grutters Journal: Eur Radiol Date: 2015-04-09 Impact factor: 5.315
Authors: Jeffrey J Swigris; Amy L Olson; Tristan J Huie; Evans R Fernandez-Perez; Joshua Solomon; David Sprunger; Kevin K Brown Journal: Am J Respir Crit Care Med Date: 2011-02-17 Impact factor: 21.405
Authors: Sarah M Ryan; Nichole E Carlson; Harris Butler; Tasha E Fingerlin; Lisa A Maier; Fuyong Xing Journal: J Med Imaging (Bellingham) Date: 2022-03-08